PeptoPlus

← All products

TIRZE
Approved medicine

Tirzepatide

Dual GIP and GLP-1 agonist for weight loss and weight maintenance.

Class
Dual GIP and GLP-1 agonist
Used for
Weight loss and type 2 diabetes (by product)

Read the details Verify your code

Illustration of a peptide molecule near a cell membrane

Mode of action

  • Switches on GIP receptors
  • Switches on GLP-1 receptors
  • Together they help control appetite, energy intake and blood sugar

Purpose

Weight loss and long-term weight maintenance in eligible patients. Some products are approved for type 2 diabetes.

Injection strengths (approved label)

2.5 mg/0.5 mL5 mg/0.5 mL7.5 mg/0.5 mL10 mg/0.5 mL12.5 mg/0.5 mL15 mg/0.5 mL

Route

Injection under the skin (subcutaneous), once a week. In trials: start at 2.5 mg and add 2.5 mg every 4 weeks.

Which receptors it switches on

ReceptorWhat it does
GLP-1Lowers appetite, slows stomach emptying, helps insulin releaseYes
GIPHelps insulin release and appetite and energy controlYes
GlucagonBeing studied for raising energy useNo

SURMOUNT-1: weight loss by dose

5 mg
15.0%
10 mg
19.5%
15 mg
20.9%
Placebo
3.1%
57%lost 20% or more on 15 mg (placebo: 3%)
91%lost 5% or more on 15 mg (placebo: 35%)
22.9%average loss on 15 mg after 3 years (placebo: 2.1%)

Source: SURMOUNT-1 (ADA 2022; Lilly release, April 2022); 176-week results reported by Healio, 2024. Average % of body weight lost at 72 weeks.

Side effects: what the trials showed

About 80% had at least one side effect on tirzepatide (placebo: 72%); 4–7% stopped because of side effects. Common stomach effects in trials: nausea, vomiting, diarrhea and constipation. Doctors also check for dehydration, gallbladder disease and pancreatitis.

Source: ZEPBOUND prescribing information (DailyMed); SURMOUNT-1 trial. The label on every PeptoPlus unit hides a one-time code under a scratch layer, with a QR beside it. Scan it to check that the code was issued by PeptoPlus.